These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 29891430

  • 1. Association of metals with the risk and clinical characteristics of Parkinson's disease.
    Kim MJ, Oh SB, Kim J, Kim K, Ryu HS, Kim MS, Ayton S, Bush AI, Lee JY, Chung SJ.
    Parkinsonism Relat Disord; 2018 Oct; 55():117-121. PubMed ID: 29891430
    [Abstract] [Full Text] [Related]

  • 2. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S, Pradhan R, Paul P, Das M, Gupta A, Ghosh P, Chatterjee S.
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [Abstract] [Full Text] [Related]

  • 3. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
    Jiménez-Jiménez FJ, Molina JA, Aguilar MV, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, de Bustos F, Martínez-Salio A, Ortí-Pareja M, Zurdo M, Martínez-Para MC.
    J Neural Transm (Vienna); 1998 Sep; 105(4-5):497-505. PubMed ID: 9720977
    [Abstract] [Full Text] [Related]

  • 4. Serum uric acid levels and freezing of gait in Parkinson's disease.
    Ou R, Cao B, Wei Q, Hou Y, Xu Y, Song W, Zhao B, Shang H.
    Neurol Sci; 2017 Jun; 38(6):955-960. PubMed ID: 28251464
    [Abstract] [Full Text] [Related]

  • 5. Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson's disease.
    Kim JE, Lee HS, Jang W.
    Front Aging Neurosci; 2023 Jun; 15():1282367. PubMed ID: 38020782
    [Abstract] [Full Text] [Related]

  • 6. Association of Parkinson's disease with altered serum levels of lead and transition metals among South Indian subjects.
    Kumudini N, Uma A, Devi YP, Naushad SM, Mridula R, Borgohain R, Kutala VK.
    Indian J Biochem Biophys; 2014 Apr; 51(2):121-6. PubMed ID: 24980015
    [Abstract] [Full Text] [Related]

  • 7. Freezing of gait in patients with advanced Parkinson's disease.
    Giladi N, Treves TA, Simon ES, Shabtai H, Orlov Y, Kandinov B, Paleacu D, Korczyn AD.
    J Neural Transm (Vienna); 2001 Apr; 108(1):53-61. PubMed ID: 11261746
    [Abstract] [Full Text] [Related]

  • 8. [Metals and oxidative stress in Parkinson's disease from industrial areas with exposition to environmental toxins or metal pollution].
    Squitti R, Gorgone G, Binetti G, Ghidoni R, Pasqualetti P, Draicchio F, Albini E, Benedetti L, Lucchini R, Rossini PM.
    G Ital Med Lav Ergon; 2007 Apr; 29(3 Suppl):294-6. PubMed ID: 18409692
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH, Tang BS, Song CY, Xu Q, Lou MX, Liu ZH, Yu RH, Yan XX, Guo JF.
    Neurosci Lett; 2013 Nov 27; 556():109-12. PubMed ID: 24135335
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Serum copper, zinc and selenium levels in Tunisian patients with Parkinson's disease.
    Younes-Mhenni S, Aissi M, Mokni N, Boughammoura-Bouatay A, Chebel S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G, Sfar MT, Sfar MH.
    Tunis Med; 2013 Jun 27; 91(6):402-5. PubMed ID: 23868039
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 27; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD, Blaabjerg M, Binzer M, Kamal A, Thagesen H, Kjaer TW, Stenager E, Gramsbergen JBP.
    J Neurochem; 2017 May 27; 141(4):614-625. PubMed ID: 28244186
    [Abstract] [Full Text] [Related]

  • 18. Serum levels of zinc and copper in patients with Parkinson's disease.
    Jiménez-Jiménez FJ, Fernández-Calle P, Martínez-Vanaclocha M, Herrero E, Molina JA, Vázquez A, Codoceo R.
    J Neurol Sci; 1992 Oct 27; 112(1-2):30-3. PubMed ID: 1469436
    [Abstract] [Full Text] [Related]

  • 19. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R, Zhang BR, Pohle S, Klebe S, Lorenz D, Herzog J, Wilms H, Deuschl G, Krack P.
    Brain; 2002 Apr 27; 125(Pt 4):871-9. PubMed ID: 11912119
    [Abstract] [Full Text] [Related]

  • 20. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T, Ando T, Yamaguchi K, Nakajima T, Shirane R, Itoh M, Tominaga T.
    J Neurosurg; 2004 Apr 27; 100(4):606-10. PubMed ID: 15070112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.